



Partner with Us

Infectious Diseases & Vaccine Development



INDUSTRY PARTNERSHIP HIGHLIGHTS

- Vaccine breakthroughs for Ebola, Zika, cholera, MERS/SARS, influenza, malaria, and typhoid
- National vaccine trial network leadership
- Conducted trials of the live attenuated intranasal flu vaccine and multiple pandemic flu vaccines requiring rapid implementation
- Leader in testing COVID-19 vaccine candidates including pediatric testing of Moderna Covid-19 vaccine
- Led Novavax Covid-19 trial that resulted in emergency authorization

The University of Maryland School of Medicine has active partnerships in over 40 countries, where our faculty are driving groundbreaking collaborations and advancing transformative technologies that are shaping the future of global health. We invite Biopharmaceutical R&D partners to **join us in accelerating scientific discovery and delivering real-world impact through strategic innovation**. Our institutes for Human Virology and Genome Sciences, and the Center for Vaccine Development and Global Health are leaders in infectious diseases research and vaccine innovation.

Preclinical Development Assets

Humanized mouse models allowing collaborators to study human-specific diseases, immune responses, and drug effects

Genetic sequencing centers including CLIA lab

Clinical Development Capabilities

Ambulatory & residential research facilities with strong track record of subject accruals to target, including pediatric populations

Equipped for Phases I, II, and III

Expertise in challenge trials for Influenza, Malaria (including mosquito insectary), Shigella, Diarrheagenic *E. coli*, and Cholera

National clinical research leadership in NIH Vaccine and Treatment Evaluation Unit and Infectious Disease Clinical Research Consortium executive team

Robust biostatistical support

Regulatory expertise including training, auditing/monitoring, IRB, SOP/QMP development

FDA/EMA collaborations and **IND/IDE experience**

HEOR and Post-Market

Real world data including EHR and health care claims

Racially and ethnically **diverse 2.3 million patient health system** and **community engaged research** methodologies

Advanced analytics including large language model development

Novel tool development such as real time risk stratification at point of care

The Future
of Medicine
is Collaboration



Let's discuss collaborating, contact:

Claire Brown, MS

Director of Industry Partnerships

Claire.Brown@som.umaryland.edu

www.medschool.umaryland.edu